Kim Papp

48.7k total citations · 27 hit papers
542 papers, 32.6k citations indexed

About

Kim Papp is a scholar working on Immunology, Dermatology and Rheumatology. According to data from OpenAlex, Kim Papp has authored 542 papers receiving a total of 32.6k indexed citations (citations by other indexed papers that have themselves been cited), including 407 papers in Immunology, 278 papers in Dermatology and 97 papers in Rheumatology. Recurrent topics in Kim Papp's work include Psoriasis: Treatment and Pathogenesis (384 papers), Dermatology and Skin Diseases (265 papers) and Asthma and respiratory diseases (86 papers). Kim Papp is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (384 papers), Dermatology and Skin Diseases (265 papers) and Asthma and respiratory diseases (86 papers). Kim Papp collaborates with scholars based in Canada, United States and Germany. Kim Papp's co-authors include Richard G. Langley, Kristian Reich, Kenneth B. Gordon, Craig L. Leonardi, C.E.M. Griffiths, Shu Li, Melinda Gooderham, Alan Menter, Andrew Blauvelt and Cynthia Guzzo and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Kim Papp

507 papers receiving 31.7k citations

Hit Papers

Secukinumab in Plaque Psoriasis — Results of Two ... 2005 2026 2012 2019 2014 2008 2008 2005 2005 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
    2014 1.5k citations Richard G. Langley, Mark Lebwohl et al. profile →
  2. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
    2008 1.4k citations Kim Papp, Kenneth B. Gordon et al. profile →
  3. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
    2008 1.1k citations Kim Papp, Richard G. Langley et al. profile →
  4. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
    2005 852 citations Alice B. Gottlieb, Kim Papp et al. profile →
  5. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
    2005 838 citations Kristian Reich, Kim Papp et al. profile →
  6. Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
    2012 729 citations Kim Papp et al. profile →
  7. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
    2007 695 citations Kenneth B. Gordon, Richard G. Langley et al. Journal of the American Academy of Dermatology profile →
  8. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
    2015 658 citations Kristian Reich, Mark Lebwohl et al. profile →
  9. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    2016 650 citations Kenneth B. Gordon, Andrew Blauvelt et al. profile →
  10. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
    2017 637 citations Andrew Blauvelt, Kim Papp et al. Journal of the American Academy of Dermatology profile →
  11. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
    2007 559 citations Kim Papp, Richard G. Langley et al. British Journal of Dermatology profile →
  12. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
    2005 557 citations Kim Papp et al. British Journal of Dermatology profile →
  13. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
    2015 483 citations Kim Papp, Kristian Reich et al. Journal of the American Academy of Dermatology profile →
  14. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study
    2009 462 citations Kim Papp et al. profile →
  15. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
    2018 452 citations Kenneth B. Gordon, Bruce Strober et al. profile →
  16. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
    2017 413 citations Kristian Reich, Kim Papp et al. profile →
  17. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
    2017 392 citations Kim Papp, Andrew Blauvelt et al. profile →
  18. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis
    2016 376 citations Kim Papp, Kristian Reich et al. British Journal of Dermatology profile →
  19. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)
    2005 373 citations Kim Papp et al. profile →
  20. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
    2021 350 citations Emma Guttman‐Yassky, Henrique D. Teixeira et al. profile →
  21. Topical tofacitinib for atopic dermatitis: a phase II a randomized trial
    2016 320 citations Robert Bissonnette, Kim Papp et al. British Journal of Dermatology profile →
  22. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
    2019 255 citations Emma Guttman‐Yassky, Diamant Thaçi et al. Journal of Allergy and Clinical Immunology profile →
  23. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
    2022 219 citations April W. Armstrong, Melinda Gooderham et al. Journal of the American Academy of Dermatology profile →
  24. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies
    2021 199 citations Kim Papp, Jacek C. Szepietowski et al. Journal of the American Academy of Dermatology profile →
  25. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
    2022 173 citations Bruce Strober, Diamant Thaçi et al. Journal of the American Academy of Dermatology profile →
  26. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
    2021 169 citations Kristian Reich, Kim Papp et al. profile →
  27. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
    2022 122 citations Eric L. Simpson, Kim Papp et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kim Papp Canada 85 24.4k 16.3k 7.2k 4.8k 4.3k 542 32.6k
Kristian Reich Germany 80 20.2k 0.8× 14.0k 0.9× 5.0k 0.7× 4.1k 0.8× 3.7k 0.9× 497 26.2k
Alice B. Gottlieb United States 90 23.1k 0.9× 12.3k 0.8× 8.9k 1.2× 2.8k 0.6× 3.5k 0.8× 602 31.4k
Alan Menter United States 80 19.1k 0.8× 12.2k 0.7× 4.7k 0.7× 3.3k 0.7× 3.5k 0.8× 387 25.4k
Richard G. Langley Canada 67 14.7k 0.6× 9.6k 0.6× 3.4k 0.5× 2.6k 0.5× 2.7k 0.6× 264 19.1k
Kenneth B. Gordon United States 61 13.8k 0.6× 7.7k 0.5× 3.3k 0.5× 2.2k 0.5× 2.5k 0.6× 206 16.7k
Diamant Thaçi Germany 56 8.3k 0.3× 7.7k 0.5× 3.2k 0.4× 2.5k 0.5× 1.7k 0.4× 375 13.5k
Craig L. Leonardi United States 45 11.4k 0.5× 6.4k 0.4× 2.6k 0.4× 2.0k 0.4× 2.0k 0.5× 133 14.1k
Wolf‐­Henning Boehncke Germany 55 8.7k 0.4× 4.4k 0.3× 2.7k 0.4× 1.4k 0.3× 1.3k 0.3× 356 13.2k
Lone Skov Denmark 58 6.6k 0.3× 5.5k 0.3× 1.9k 0.3× 1.7k 0.4× 1.1k 0.3× 389 12.9k
Dafna D. Gladman Canada 102 30.8k 1.3× 3.4k 0.2× 38.1k 5.3× 1.2k 0.2× 3.9k 0.9× 959 47.9k

Countries citing papers authored by Kim Papp

Since Specialization
Citations

This map shows the geographic impact of Kim Papp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Papp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Papp more than expected).

Fields of papers citing papers by Kim Papp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kim Papp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Papp. The network helps show where Kim Papp may publish in the future.

Co-authorship network of co-authors of Kim Papp

This figure shows the co-authorship network connecting the top 25 collaborators of Kim Papp. A scholar is included among the top collaborators of Kim Papp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim Papp. Kim Papp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lebwohl, Mark, Atul Deodhar, Sergio Schwartzman, et al.. (2025). Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events. Dermatology and Therapy. 15(1). 161–188. 2 indexed citations
2.
Östör, Andrew J.K., Filip Van den Bosch, Kim Papp, et al.. (2025). Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials. Rheumatology and Therapy. 12(6). 1103–1123.
3.
Rosmarin, David, Amit G. Pandya, Thierry Passeron, et al.. (2025). Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo. Dermatology and Therapy. 15(12). 3703–3716.
4.
Östör, Andrew J.K., Filip Van den Bosch, Kim Papp, et al.. (2024). Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and Therapy. 11(3). 633–648. 9 indexed citations
5.
Prajapati, Vimal H., Charles Lynde, Melinda Gooderham, et al.. (2024). Considerations for defining and diagnosing generalized pustular psoriasis. Journal of the European Academy of Dermatology and Venereology. 39(3). 487–497. 4 indexed citations
6.
Albrecht, Lorne, Jennifer Beecker, Isabelle Delorme, et al.. (2024). 53822 Longitudinal evaluation of the psoriasis epidemiology screening tool (PEST) in patients with moderate to severe psoriasis: Results from the PURE Registry. Journal of the American Academy of Dermatology. 91(3). AB250–AB250.
7.
Östör, Andrew J.K., Filip Van den Bosch, Kim Papp, et al.. (2024). Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 2 Trial. SKIN The Journal of Cutaneous Medicine. 8(6). s446–s446.
8.
Eichenfield, Lawrence F., Eric L. Simpson, Kim Papp, et al.. (2024). Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies. American Journal of Clinical Dermatology. 25(4). 669–683. 8 indexed citations
9.
Bissonnette, Robert, Linda Stein Gold, Leon Kircik, et al.. (2024). 53928 Tapinarof Cream 1% Once Daily: Interim Analysis of ADORING 3 Phase 3 Long-term Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis. Journal of the American Academy of Dermatology. 91(3). AB88–AB88. 2 indexed citations
10.
Behrens, Frank, Mauro Waldemar Keiserman, Kim Papp, et al.. (2024). Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 1 Trial. SKIN The Journal of Cutaneous Medicine. 8(6). s445–s445.
11.
Armstrong, April W., Peter Foley, Yan Liu, et al.. (2024). Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis. Dermatology and Therapy. 14(9). 2577–2589. 5 indexed citations
12.
Blauvelt, Andrew, Richard G. Langley, Patrick Branigan, et al.. (2024). Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy. SHILAP Revista de lepidopterología. 4(5). 100287–100287. 3 indexed citations
13.
Strober, Bruce, Andrew Blauvelt, Richard B. Warren, et al.. (2024). Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2). Journal of the European Academy of Dermatology and Venereology. 38(8). 1543–1554. 27 indexed citations
14.
Merola, Joseph F., Lawrence Charles Parish, Lyn Guenther, et al.. (2023). Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology. 90(3). 485–493. 13 indexed citations
15.
Armstrong, April W., L. Puig, Kim Papp, et al.. (2023). 43927 The Impact of Treatment with Guselkumab on Skin-related Quality of Life in Male and Female Patients with Moderate to Severe Psoriasis: Results from the VOYAGE 1 and 2 Trials. Journal of the American Academy of Dermatology. 89(3). AB235–AB235. 1 indexed citations
16.
Papp, Kim, Andrew Blauvelt, L. Puig, et al.. (2023). Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. Journal of the American Academy of Dermatology. 89(6). 1149–1158. 30 indexed citations
17.
Guttman‐Yassky, Emma, Diamant Thaçi, Aileen L. Pangan, et al.. (2019). Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 145(3). 877–884. 255 indexed citations breakdown →
18.
Bissonnette, Robert, Kim Papp, Yves Poulin, et al.. (2016). Topical tofacitinib for atopic dermatitis: a phase II a randomized trial. British Journal of Dermatology. 175(5). 902–911. 320 indexed citations breakdown →
19.
Thaçi, Diamant, Gil Yosipovitch, Kim Papp, et al.. (2015). Effects of apremilast on pruritus in patients with moderate to severe plaque psoriasis : results from the ESTEEM 1 and 2 trials. Ghent University Academic Bibliography (Ghent University). 1 indexed citations
20.
Papp, Kim, Richard G. Langley, Bárður Sigurgeirsson, et al.. (2012). Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. British Journal of Dermatology. 168(2). 412–421. 296 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kristian Reich Breakdown of academic impact, for papers by Alice B. Gottlieb Breakdown of academic impact, for papers by Alan Menter Breakdown of academic impact, for papers by Richard G. Langley Breakdown of academic impact, for papers by Kenneth B. Gordon Breakdown of academic impact, for papers by Diamant Thaçi Breakdown of academic impact, for papers by Craig L. Leonardi Breakdown of academic impact, for papers by Wolf‐­Henning Boehncke Breakdown of academic impact, for papers by Lone Skov Breakdown of academic impact, for papers by Dafna D. Gladman
Rankless by CCL
2026